|
|
MIVT:
MIV THERAPEUTICS´FIRST IN-MAN STUDY DATA ‘VERY ENCOURAGING’
ACCORIDNG TO SISM RESEARCH MORNING NOTE
NEW YORK--(BUSINESS WIRE)--(Investrend
Research Syndicate) Ernest C. Schlotter, a senior analyst with
Investrend affiliate SISM Research and a four star analyst according
to StarMine, has reiterated his “Speculative Buy/4”
Rating and 12-18 month target price of $2.50 for MIV Therapeutics,
Inc. (OTCBB: MIVT - News) in a Morning Note. Full
Report-HTM Analyst
Report - PDF |
| |
|
| |
MIVT:
MIV PRELIMINARY NINE-MONTH HUMAN DATA AFFIRMS EXCELLENT SAFETY
AND EFFICACY OF VESTASYNC™ POLYMER-FREE-DRUG-ELUTING STENT
ATLANTA--(BUSINESS WIRE)--MIV
Therapeutics, Inc. (OTCBB:MIVT - News) (Frankfurt:MIV - News),
a leading developer of next-generation coatings and advanced
drug-delivery systems for cardiovascular stents and other implantable
medical devices, announced that nine month results from the
first-in-man (FIM) MIVT Pilot Trial of its VESTAsync™
drug-eluting stent suggest that the stent has the potential
for superior safety and equivalent efficacy when compared to
currently available drug-eluting stents. Jose Costa, M.D. of
Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil
discussed the preliminary data in a moderated poster presentation
yesterday at the 57th Annual Scientific Sessions of the American
College of Cardiology in Chicago. The presentation titled, “Preliminary
Results of the Hydroxyapatite Non-Polymer-Based Sirolimus-Eluting
Stent for the Treatment of Single de novo Coronary Lesions:
A First-in-Human Analysis of a Third-Generation Drug-Eluting
Stent System” concluded that the VESTAsyncTM polymer-free
nanoscale microporous hydroxyapatite stent demonstrates excellent
efficacy and safety. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS RECEIVES 2008 FROST & SULLIVAN NORTH AMERICA
AWARD FOR TECHNOLOGY INNOVATION
ATLANTA, GA--(MARKET WIRE)--Feb
25, 2008 -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F
- News), a leading developer of next-generation coatings and
advanced drug delivery systems for cardiovascular stents and
other implantable medical devices, today announced that the
company received the Frost & Sullivan 2008 North America
Technology Innovation Award in the field of interventional cardiology.
Frost & Sullivan will present the award to Dr. Mark Landy,
president and chief executive officer of MIV, at the 2008 Excellence
in Medical Technologies & Life Sciences Awards Banquet on
Wednesday, March 12, 2008 at the Hyatt Fisherman's Wharf in
San Francisco. Full Report-HTM
|
| |
|
| |
MIVT:
MIV THERAPEUTICS APPOINTS MARK LANDY TO ADDITIONAL POST OF CHIEF
EXECUTIVE OFFICER
ATLANTA, GA--(MARKET WIRE)--Jan
7, 2008 -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F
- News), a leading developer of next-generation coatings and
advanced drug delivery systems for cardiovascular stents and
other implantable medical devices, today announced that Dr.
Mark Landy, president, will assume the additional position of
chief executive officer of the company effective today. He assumes
this position from Alan Lindsay, who will remain chairman of
the board of MIV Therapeutics. Full
Report-HTM |
| |
|
| |
MIVT:
MIVT THERAPEUTICS RECEIVES INDIA REGULATORY APPROVAL FOR TWO
BARE METAL STENTS
ATLANTA, GA--(MARKET WIRE)--Nov
12, 2007 -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F
- News), a leading developer of next-generation coatings and
advanced drug delivery systems for cardiovascular stents and
other implantable medical devices, announces that the Drugs
Controller General of India (DCGI), the governmental agency
with regulatory authority over medical products, has approved
two of the Company's bare metal stents for manufacture and sale
in India. Full Report-HTM
|
| |
|
| |
MIVT:
MIVT THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM FIRST HUMAN
STUDY WITH ITS VESTASYNC STENT
ATLANTA, GA--(MARKET WIRE)--Oct
16, 2007 -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F
- News), a leading developer of next-generation coatings and
advanced drug delivery systems for cardiovascular stents and
other implantable medical devices, announces that results of
the first-in-man safety study with the Company's drug-eluting
stent will be presented at the Transcatheter Cardiovascular
Therapeutics (TCT) 2007 conference, to be held October 20-25
at the Washington Convention Center in Washington, D.C. Full
Report-HTM |
| |
|
| |
MIVT:
RESULTS OF FIRST-IN-MAN STUDY WITH MIVT LOW DOSE POLYMER-FREE
DRUG-ELUTING STENT TO BE PRESENTED AT TCT CONFERENCE
ATLANTA, GA--(MARKET WIRE)--Oct
16, 2007 -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F
- News), a leading developer of next-generation coatings and
advanced drug delivery systems for cardiovascular stents and
other implantable medical devices, announces that results of
the first-in-man safety study with the Company's drug-eluting
stent will be presented at the Transcatheter Cardiovascular
Therapeutics (TCT) 2007 conference, to be held October 20-25
at the Washington Convention Center in Washington, D.C. Full
Report-HTM |
| |
|
| |
MIVT:
MIVT THERAPEUTICS ANNOUNCES RESEARCH COLLOBARATION WITH SMITH
& NEPHEW
ATLANTA, GA--(MARKET WIRE)--Sep
27, 2007 -- MIV Therapeutics (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F
- News), a leading developer of next-generation coatings and
advanced drug delivery systems for cardiovascular stents and
other implantable medical devices, today announced a research
collaboration with contributions in kind from both Smith &
Nephew and MIV Therapeutics to develop new coatings and drug
delivery systems for orthopedic devices. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS APPOINTS ERNST & YOUNG AS NEW AUDITOR
Appointment Addresses Company's
Need to Increase International Capabilities After Recent Acquisitions.
Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS NAMES METHODIST HOSPITAL RESEARCH CARDIOLOGIST
DR. GREG KALUZA TO SCIENTIFIC ADVISORY BOARD
World Renowned Specialist
Contributes Extensive Clinical Expertise as Company Moves to
Next Phase of Development and Commercialization. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS ANNOUNCES START OF CLINICAL TRIAL MARKING FIRST
EVER HUMAN IMPLANTATION OF A HYDROXYAPATITE COATED STENT
Trial to Study Safety and
Efficacy of One of the Company's Proprietary Polymer-Free Drug-Eluting
Stent Technologies. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS APPOINTS INTERNATIONALLY RENOWNED CARDIOLOGIST
AND CHIEF EXECUTIVE OFFICER OF KAILASH HEART INSTITUTE AS CLINICAL
ADVISOR
World Renowned Specialist
Contributes Extensive Clinical Trial Expertise. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS ANNOUNCES RENOWNED RESEARCHER TO DETAIL MILESTONE
PRE-CLINICAL RESULTS AT PROMINENT INTERNATIONL CONFERENCE EUROPCR
2007
Third Party Presentation
to Feature Study Showing Proprietary Technology Matches or Outperforms
Current Stent Technology in Key Categories. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS ESTABLISHES PRESENCE IN EUROPE AND ENGAGES
INFLUENTIAL BUSINESS DEVELOPMENT FIRM QUILT SOLUTIONS
MIVT to Open Office in Basel,
Switzerland, to Focus on Sales and Marketing of Recently Acquired
CE-Marked Products into Lucrative European Markets. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS TARGETS MULTIBLILION MEDICAL DEVICE MARKET
IN RESEARCH NOTE BY INVESTREND AFFILIATE SISM RESEARCH
This month, MIVT generated
its first revenue in Company history. These sales clearly vali-date
the mission of the Company to become a leader in interventional
cardiology. MIVT is now targeting an eight billion dollar cardiovascular
stent market that includes Europe, Asia, and India. In addition,
MIVT expects to bring its polymer-free hydroxyapatite coating
plat-form to the market place soon. Trial programs in 2006 indicate
that MIVT’s polymer-free technology is at least as good,
and in some cases better than, Johnson & Johnson's Cypher
stent, currently the world’s best-selling drug-eluting
stent. First human implantation is planned within the next few
months. Stroke is the third leading cause of death and one of
the most feared complications of surgery. Scientific data show
that the extent of stroke following heart surgery is alarming.
MIVT’s novel proprietary device targets a $58 billion
industry to prevent embolic strokes after cardiac surgery. The
Company has entered a rapid phase of testing and regulation
for its device. Market entry for the product is expected in
Europe within 12 months and in the US within 24 months. Today,
MIVT is an undiscovered company with a huge opportunity in a
very large market. We maintain our view that MIVT is still significantly
undervalued and consequently reaffirm our 12-month target price
of $2.50. Full
Analyst Report - PDF |
| |
|
| |
MIVT:
MIV THERAPEUTICS ANNOUNCES FIRST EVER REVENUES FROM CARDIOVASULAR
PRODUCTS APPROVED FOR EUROPEAN AND OTHER MARKETS
Sales of Recently Acquired
CE-Marked Devices Initiate Commercialization of Broad and Expanding
Product Portfolio. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS HIGHLIGHTS HIGH-GROWTH BUSINESS MODEL, NEXT
GENERATION STENT TECHNOLOGIES AND TARGETED $8 BILLION MARKET
IN UPDATED INVESTOR FACT SHEET
Company Details Global Reach
with Recent Acquisition of Biosync Scientific to Expand Product
Offerings and Manufacturing Capabilities. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS ANNOUNCES ADDITION OF EIGHT NEW APPROVED PRODUCTS
FOLLOWING RECENT ACQUISTION OF INDIA-BASED STENT MANUFACTURER
CE-Marked Products Already
Approved for Commercialization in Europe, India, Asia and Other
Highly Lucrative Markets. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS ANNOUNCES ADDITION OF VETERAN MANAGEMENT TEAM
FOLLOWING RECENT ACQUISTION OF INDIA-BASED BIOSYNC
Renowned Biosync Team to
Accelerate Commercialization of Next Generation Stents Targeting
$8 Billion Market. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS ANNOUNCES PIVOTAL TEST RESULTS FURTHER VALIDATING
COMPANY STENT COATINGS MEET CRITICAL FDA FATIGUE GUIDELINES
Bench Test Merged Biosync
Stent Platform with Company's Biocompatible Coating, Validating
Milestone Acquisition of India-Based Subsidiary. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS COMPLETES ACQUISTION OF BIOSYNC TO EXPAND OPERATIONS
AND ACCELERATE COMMERCIALIZATION IN FAST-GROWING MARKET
Publications in New England
Journal of Medicine Further Validates Need for Company's Novel
Technology in Estimated $58 Billion Industry. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS COMPLETES ACQUISTION OF BIOSYNC TO EXPAND OPERATIONS
AND ACCELERATE COMMERCIALIZATION IN FAST-GROWING MARKET
Acquisition to Bring Seven
Valuable CE Marked Products and Highly Competitive Bare Metal
Stent Platform. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS RELEASES CEO LETTER TO SHAREHOLDERS HIGHLIGHTING
RECENT STRATEGIC ACHIEVEMENTS AND PROGRESS
CEO Cites Recent Milestone
Agreement to Acquire China-Based Vascore Medical and India-Based
Biosync Scientific to Accelerate Commercialization of Next Generation
Stent Technology. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS EXECUTES PRIVATE FINANCINGS FOR $4 MILLION
TO SUPPORT ACQUISTIONS, DEVELOPMENT AND DISTRIBUTION OF NEXT
GENERATION STENTS
Placement Follows Recent
Agreements to Acquire Established Indian and Chinese Interventional
Cardiology Companies. Full
Report-HTM |
| |
|
| |
MIVT:
INVESTREND AFFILIATE SISM RESEARCH ‘MORNING NOTE’
REITERATES MIV THERAPEUTICS `BUY/4 RATING’ $2.50 TARGET
VALUATION, CITING PLANS TO INTRODUCE NEW PRODUCTS IN EUROPE
KEY GLOBAL MARKETS NEXT QUARTER
MIV Therapeutics (OTCBB:
MIVT) announced Biosync’s seven new CE Mark-certified
cardiovascular stents and related products to be sold in India,
then Europe, Asia and Latin America. (OTCBB: MIVT) announced
Biosync’s seven new CE Mark-certified cardiovascular stents
and related products to be sold in India, then Europe, Asia
and Latin America. Full
Report-HTM ANALYST-REPORT-PDF
ANALYST-REPORT-PDF
IN GERMAN |
| |
|
| |
MIVT:
MIV THERAPEUTICS ANNOUNCES MARKET LAUNCH OF THE GENX CRCO STENT
AND SEVEN ASSOCIATED INTERVENTION CARDIOLOGY PRODUCTS BY BIOSYNC
SCIENTIFIC
Launch is a Key Milestone
in the Company's Mission to Deliver a Broad Range of Products
to the Interventional Cardiology Community. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS INC GAINS 31.6% ON 13X VOLUME
December 13, 2006 (FinancialWire)
MIV Therapeutics Inc (OTCBB: MIVT) gained 31.65% Tuesday on
volume of 2,455,106, which was almost 13 times its three-month
average 190,280, to end the day at $1.04. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS INC GAINS 33.9% ON 7X VOLUME
December 12, 2006 (FinancialWire)
Miv Therapeutics Inc (OTCBB: MIVT) gained 33.9% Monday on volume
of 1,232,695, which was seven times its three-month average
173,838, to end the day at $0.79. Full
Report-HTM |
| |
|
| |
MIVT:MIV
THERAPEUTICS EXECUTES MILESTONE AGREEMENT TO ACQUIRE BIOSYNC
SCIENTIFIC, A LEADING INDIAN INTERVENTIONAL CARDIOLOGY COMPANY
Acquisition Provides MIVT
with Highly Competitive CE Marked Bare Metal Stent Platform.
Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS INC GAINS 18% ON 2X VOLUME
December 11, 2006 (FinancialWire)
MIV Therapeutics Inc (OTCBB: MIVT) gained 18% Friday on volume
of 408,585, which was more than twice its three-month average
168,178, to end the day at $0.59. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS ‘BUY/4’ RATING, $2.50 TARGET VALUATION
REITERATED IN RESEARCH NOTE BY INVESTREND AFFILIATE SISM RESEARCH,
INDICATING GRATER MARKET POTENTIAL AND CITING RECENT SUPERIOR
PERFORMANCE OF STENT COATING TECHNOLOGIES IN RECENT TESTS
MIVT's Biocompatible Polymer-Free
Drug-Eluting Stent Coating Technologies Shown in Tests to be
Better Than the Industry's Benchmark Cypher Stent, One of the
World's Best Selling Drug-Eluting Stents. Full
Report-HTM ANALYST
REPORT-PDF |
| |
|
| |
MIVT:
MIV THERAPEUTICS MAINTAINS ‘BUY/4’ Rating and $2.50
12-MONTH TARGET VALUATION IN RESEARCH NOTE BY INVESTREND AFFILIATE
SISM RESEARCH
MIV Therapeutics (OTCBB:
MIVT) Recent tests have sown MIV Therapeutics’ (OTCBB:
MIVT) biocompatible polymer-free drug-eluting stent coating
technologies shown to be Better Than the Industry’s Benchmark
Cypher Stent. Full
Report-HTM Research
Note - PDF |
| |
|
| |
MIVT:
MIV THERAPEUTICS INC. GAINS 42.11% ON 10X VOLUME
December 1, 2006 (FinancialWire) MIV Therapeutics Inc (OTCBB:
MIVT) gained 42.11% Thursday on volume of 1,501,577, which was
more than ten times its three-month average 142,869, to end
the day at $0.54. Full
Report-HTM
|
| |
|
| |
MIVT:
MIV THERAPEUTICS ANNOUNCES COMPANY’S BIOCOMPATIBLE STENTS
MATCHES OR OUTPERFORMS WORLD’S LEADING DRUG-ELUTING STENT
IN KEY CATEGORIES
Excellent Results from Preclinical Study of Biocompatible Polymer-Free
Drug Eluting Stent Coating Technologies Paves the Way Towards
Human Trials. Full
Report-HTM
|
| |
|
| |
MIVT:
HUMAN TRIALS ARE ONLY A SHORT PERIOD AWAY
MIVT has extended its corporate success into 2006. In preparation
for coming clinical trials that will commence in early 2007,
the Company successfully completed an exten-sive range of animal
studies, confirming the biocompatibility and safety of its crown
technologies for the cardiovascular industry: polymer-free coatings
for stents. Full
Analyst -Report-PDF
|
| |
|
| |
MIVT:
MIV THERAPEUTICS ANNOUNCES
TIMELINE FOR FIRST HUMAN IMPLANTATION OF HAP NANO-FILM COATED
STENT
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT
- News; FWB:MIV), a leading developer of next-generation biocompatible
drug-eluting stents, announced today that it intends to begin
the first human implants of a HAp NanoFilm coated stent early
in 2007. Full
Report-HTM
|
| |
|
| |
MIVT:
MIV THERAPEUTICS DETAIL RESEARCH RESULTS SHOWING EXCELLENT PERFORMANCE
OF BREAKTHROUGH STENT COATINGS AT TCT CONFERENCE
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics (OTCBB:MIVT - News;
FWB:MIV), announced that Dr. Greg Kaluza, Scientific Director,
Center for Research in Cardiovascular Interventions at The Methodist
Hospital Research Institute, Houston, TX, who directed the independent
preclinical study of MIVT's stent coatings will present recent
results of a long-term animal study of its proprietary stent
coating technology at the Annual Transcatheter Cardiovascular
Therapeutics (TCT) 2006 conference in Washington, D.C., the
field's largest scientific meeting. Full
Report-HTM
|
| |
|
| |
MIVT:
MIV THERAPEUTICS CITED AS LEADING TECHNOLOGY INNOVATOR IN CARDIOVASCULAR
DEVICE INDUSTRY REPORT BY FROST & SULLIVAN
ATLANTA--(BUSINESS WIRE)--Sept. 19, 2006--MIV Therapeutics (OTCBB:MIVT
- News; FWB:MIV), a leading developer of next-generation biocompatible
coatings and advanced drug delivery systems for cardiovascular
stents and other implantable medical devices, has announced
that the widely respected global consulting firm Frost &
Sullivan has cited the Company's innovative stent coating technology
as among the most advanced of the emerging class of biocompatible
third generation cardiac stents under development. Full
Report-HTM
|
| |
|
| |
MIVT:
MIV THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE VASCORE MEDICAL
CO. LTD., LEADING CHINESE MANUFACTURER OF ADVANCED CARDIOVASCULAR
STENTS
VANCOUVER, B.C.--(BUSINESS WIRE)--Sept. 13, 2006--MIV Therapeutics
(OTCBB:MIVT - News; FWB:MIV), a leading developer of next-generation
biocompatible coatings and advanced drug delivery systems for
cardiovascular stents and other implantable medical devices,
announced that it has entered into a formal agreement to acquire,
subject to the prior satisfaction of certain conditions, Vascore
Medical (Suzhou) Co., Ltd., a China-based manufacturer of advanced
cardiovascular stents and other medical devices. Full
Report-HTM
|
| |
|
| |
MIVT:
MIV THERAPEUTICS FILES THREE NEW US PATENTS FOR BREAKTHROUGH
STROKE-PREVENTING TECHNOLOGY FROM SAGAX SUBSIDIARY
ATLANTA--(BUSINESS WIRE)--Aug. 18, 2006--MIV Therapeutics (OTCBB:MIVT
- News; FWB:MIV), a leading developer of next-generation biocompatible
coatings and advanced drug delivery systems for cardiovascular
stents and other implantable medical devices, has announced
that its subsidiary, SagaX, has filed three new patents with
the U.S. Patent Office related to a proprietary implantable
filtration device designed to help prevent common stoke complications
during and after a range of common invasive heart procedures.
Full
Report-HTM
|
| |
|
| |
MIVT:
MIV THERAPEUTICS TO UNVEIL TECHNOLOGIES TARGETING $23 BILLION
ORTHOPEDICS DEVICE MARKET
ATLANTA--(BUSINESS WIRE)--Aug. 10, 2006--MIV Therapeutics (OTCBB:MIVT
FWB:MIV), a leading developer of next-generation biocompatible
coatings and advanced drug delivery systems for cardiovascular
stents and other implantable medical devices, will unveil technology
to address multiple revenue opportunities in the $23 billion
orthopedic device market at the upcoming World Orthopedic Organization
(SICOT) conference in Buenos Aires, later this month. Full
Report-HTM
|
| |
|
| |
MIVT:
MIV THERAPEUTICS’ SUBSIDIARY SAGAX ACCELERATES DEVELOPMENT
OF SURGICAL STROKE PREVENTION DEVICE TOWARDS COMMERCIALIZATION
First Generation Device Could be Ready for Clinical Use Within
14 MonthsAdditions to SagaX Team Strengthens Management and
Accelerates Development of Novel Stroke Prevention Device. Full
Report-HTM
|
| |
|
| |
MIVT:
MIV THERAPEUTICS’ SUBSIDIARY SAGAX ACCELERATES DEVELOPMENT
OF SURGICAL STROKE PREVENTION DEVICE TOWARDS COMMERCIALIZATION
First Generation Device Could be Ready for Clinical Use Within
14 MonthsAdditions to SagaX Team Strengthens Management and
Accelerates Development of Novel Stroke Prevention Device. Full
Report-HTM
|
| |
|
| |
MIVT:
MIV THERAPEUTICS’ SUBSIDIARY SAGAX ANNOUNCES APPOINTMENT
OF NEW EXECUTIVES AND TECHNOLOGY SPECIALISTS
Additions to SagaX Team Strengthens Management and Accelerates
Development of Novel Stroke Prevention Device. Full
Report-HTM
|
| |
|
| |
MIVT:
MIV THERAPEUTICS’ HIRE NOTED PHARMACOLOGY SCIENTIST DR.
VLAD BUDZYNSKI TO DIRECT MULTIPLATFORM DRUG DELIVERY PROGRAM
Veteran Researcher and University Professor Brings Expertise
in Drug Development and Advanced Biomedical Solutions. Full
Report-HTM
|
| |
|
| |
MIVT:
MIV THERAPEUTICS’ EXECUTES AGREEMENT TO COLLABORATE ON
FUTURE DRUG ELUTING STENT TECHNOLOGIES WITH SAHAJANAND
Agreement with Stent Manufacturer to Involve Potential Cross-Licensing
and Other Development Initiatives. Full
Report-HTM
|
| |
|
| |
MIVT:
MIV THERAPEUTICS’ SHARE PRICE TARGET PROJECTION INCREASED
TO $1.77 IN NEW REPORT UPDATE FROM BEACON EQUITY RESEARCH
Company Officers Outline Recent Strategic Achievements and Product
Development Initiatives at Shareholders Meeting. Full
Report-HTM
|
| |
|
| |
MIVT:
MIV THERAPEUTICS’ SHARE PRICE TARGET PROJECTION INCREASED
TO $1.77 IN NEW REPORT UPDATE FROM BEACON EQUITY RESEARCH
Raised Share Price Target Reflects Continued Progress to Develop
Breakthrough Solutions for Stents and Drug-Delivery Systems.
Full
Report-HTM
Analyst Report |
| |
|
| |
MIVT:
MIV THERAPEUTICS 6-MONTH PRICE TARGET OF $2.50 REAFFIRMED IN
NEWLY UPDATED SISM RESEARCH REPORT
Biocompatible Stent Coating Developer's Progress Reflected in
Robust Target Price Re-Statement and Speculative Buy Rating.
Full
Report-HTM Summary
- Analyst Report |
| |
|
| |
MIVT:
MIV THERAPEUTICS HIGHLIGHTS 2005 SCIENTIFIC AND STRATEGIC MILESTONES
IN DEVELOPMENT OF NEW GENERATION BIOMEDICAL TECHNOLOGIES
Year-End Report Cites Achievements in Breakthrough Drug Delivery
and Other Solutions for Multi-Billion-Dollar Markets. Full
Report-HTM |
| |
|
| |
MIVT:MIV
THERAPEUTICS SPOTLIGHTS NEWEST CLINICAL RESULTS OF COMPANY’S
HAP-BASED STENT COATING ON BIOMEDDISCOVERIES.COM
Chief Medical Officer Describes Positive Outcomes of Pivotal
Study of Biocompatibility Coatings in Interview. Full
Report-HTM |
| |
|
| |
MIVT:MIV
THERAPEUTICS REPORTS HIGHLY FAVORABLE RESULTS IN PRECLINICAL
STUDY OF INNOVATIVE STROKE PREVENTION DEVICE
Unique Implantable Anti-Stroke Device Progress on Track for
Approval and Potential Commercialization. Full
Report-HTM |
| |
|
| |
MIVT:MIVT’S
PROPRIETARY STENT COATING TECHNOLOGY COMPLETES MAJOR LONG-TERM
ANIMAL STUDY WITH EXCELLENT RESULTS
Six-Month Study Demonstrates Unparalleled Biocompatibility and
Safety of MIVT HAp Coatings for Drug-Eluting Stent Applications.
Full
Report-HTM |
| |
|
| |
MIVT:MIVT
DISCUSSES POSITIVES INTERIM RESEARCH RESULTS ON PATH TO COMMERCIALIZE
NEW GENERATION STENT COATINGS
Chief Technology Officer Cites Interim Results of Long-Term
Animal Studies in Anticipation of Final 6 Month Results and
Report in Interview with BiomedDiscoveries.com. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS OFFICIALLY NAMED WINNER OF PRESTIGIOUS AWARD
FOR INNOVATION IN ADVANCED BIOMEDICAL TECHNOLOGY
Frost & Sullivan Report Praises MIVT Proprietary Biocompatible
Coating Technology for Stents and Other Biomedical Devices -
VANCOUVER, British Columbia--(BUSINESS WIRE)--Oct. 21, 2005--MIV
Therapeutics, Inc. a developer of next-generation biocompatible
stent coatings and drug delivery technologies, has officially
been named winner of Frost & Sullivan's prestigious 2005
Award for Technology Innovation in the Field of Advanced Medical
Coatings. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS FILES BOTH US AND INTERNATIONAL PATENTS FOR
BREAKTHROUGH SMART III NANOPARTICLE DRUG DELIVERY SYSTEM
Cutting-Edge Nanotechnology Particulate System Could Revolutionize
Drug Delivery Methods to Treat Major Diseases - VANCOUVER, British
Columbia--(BUSINESS WIRE)-- Oct. 7, 2005--MIV Therapeutics,
Inc. a developer of next-generation biocompatible stent coatings
and drug delivery technologies, today announced the filing of
landmark US and international Patent Cooperation Treaty (PCT)
patent applications for the newest member of its advanced "Smart"
drug delivery systems, designed to meet the individual needs
of millions of patients. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS GAINS 11.76% ON 2X AVERAGE VOLUME AFTER RESEACH
REPORT
October 3, 2005 (FinancialWire) MIV Therapeutics (OTCBB: MIVT)
gained 11.76% on volume of 1,005,536, almost twice its average
volume of 644,168, to close at $1.52 after Ernest C. Schlotter,
a senior analyst with Investrend Research affiliate SISM Research,
and a four-star analyst according to San Francisco-based StarMine,
reiterated his Speculative Buy/4 rating for the company and
set a new 6-month price target of $2.50. Full
Report-HTM |
| |
|
| |
MIVT:
MIV THERAPEUTICS’ SIX-MONTH SHARE PRICE TARGET RAISED
100% TO $2.50 IN NEWLY AVAILABLE REPORT FROM SISM RESEARCH
VANCOUVER, British Columbia--(BUSINESS WIRE)--Sept. 30, 2005--MIV
Therapeutics, Inc. (OTCBB:MIVT - News; Frankfurt/FSE:MIV), a
developer of next-generation biocompatible stent coatings and
drug delivery technologies, announced the availability of a
new research report targeting the Company's six-month share
price at $2.50, an approximate doubling of the recent share
value, with a speculative Buy/4 Rating. The report was issued
by SISM Research and Investment Services. Full
Report-HTML Summary
in PDF |
| |
|
| |
MIVT:
SISM RESEARCH KEEPS @ SPECULATIVE BUY; UPS TGT TO $2.5 VS $1.5;
ANALYST NOTES
Target Price Action: INCREASE, Target Price:
$2.50 (+66.67% from $1.50) Analyst
Comments: The firm notes that since their June updated
report, the stock has tripled in price but there is still considerable
value to be unlocked. MIVT gained investors confidence based
on very encouraging results from its latest animal trials which
pave the way for human clinical trials scheduled to commence
in early 2006. They also point out that MIVTapeutics also won
the prestigious Frost & Sullivan 2005 Technology Innovation
Award for Advanced Medical Coatings. MIVT's planed acquisition
of Sahajanand Medical Technologies Inc. has not yet bee completed,
but the firm believes it will be soon. SMT's state-of-the-art
production technology and worldwide distribution, combined with
MIVT's proprietary coating technology, will provide a powerful
synergy that will make MIVT a major industry player in which
MIVT become a major commercial provider in the rapidly growing
market for both cardiac and other types of implantable medical
devices, in the firm's opinion. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS INVEST IN ADDITIONAL EQUIPMENT AND SCIENTIFIC
PERSONNEL IN REFLECTION OF R&D EXPANSION
VANCOUVER, British Columbia--(BUSINESS WIRE)--Sept. 28, 2005--MIV
Therapeutics, Inc. (OTCBB:MIVT - News; Frankfurt/FSE:MIV), a
developer of next-generation biocompatible stent coatings and
drug delivery technologies, announced today that it has expanded
its comprehensive innovation and development program to improve
advanced vascular stents and internal drug-delivery systems. Full
Report - HTML |
| |
MIVT:
MIV THERAPEUTICS GAINS 26.13% ON SLIGHTLY HIGHER VOLUME
September 28, 2005 (FinancialWire) MIV Therapeutics (OTCBB:
MIVT) gained 26.13% on volume of 682,160, slightly higher than
its usual 624,059, to close at $1.40. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS’ INTELLECTUAL PROPERTY PRTFOLIO EXPANDS
TO 43 PATENTS, PATENT APPLICATONS AND LICENSES ON NOVEL TECHNOLOGIES
Aggressive IP Protection of Coating Technologies Positions Company
for Entry into $100 Billion Drug-Delivery Market. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS NAMES ARC RATJAR TO POST OF CHIEF TECHNOLOGY
OFFICER AS COMPANY ACCELERATES R&D PROGRAMS
VANCOUVER, British Columbia--(BUSINESS WIRE)--Sept. 23, 2005--MIV
Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation
biocompatible passive and drug-eluting stent coatings and drug
delivery technologies for the treatment of cardiovascular disease,
announced today that it has promoted veteran biomedical industry
engineer Arc Rajtar, MSc. Eng., to the position of Chief Technology
Officer, in a move that reflects a highly dynamic period and
accelerated pace of development at the Company. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTIC’S BREAKTHROUGH AORTIC EMBOLIC PROTECTION
DEVICE HIGHLIGHTED IN NEW INTERVIEW ON BIOMEDDISCOVERIES.COM
LOS ANGELES, Sept. 19, 2005 (PRIMEZONE) - BiomedDiscoveries.com,
http://www.biomeddiscoveries.com/bd/, the online source for
exclusive investor information in the biotechnology sector,
has made available a new Q&A-style interview with leading
international cardiac specialist, Dr. Dov Shimon, the Chief
Medical Officer and Director of MIV Therapeutics (OTC BB:MIVT.OB
- News) (Frankfurt:MIVF.F - News), which develops next-generation
biocompatible coatings and drug delivery technologies. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS PASSIVE STENT COATINGS ACCEPTED FOR PRESENTATION
AT PRESTIGIOUS WORLD CONFERENCE ON CARDIOVASULAR THERAPY
VANCOUVER, British Columbia--(BUSINESS WIRE)--Sept. 12, 2005--MIV
Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation
biocompatible stent coatings and drug delivery technologies
for the treatment of cardiovascular disease, announced that
interim results of a long-term animal study of its proprietary
ultra-thin Hydroxyapatite coating will be featured at this year's
17th annual Transcatheter Cardiovascular Therapeutics (TCT)
2005 conference in Washington, D.C. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS NEWEST TECHNOLOGY BRAKTHROUGH EXPANDS FAMILY
OF PROPERITARY “SMART” DRUG DELVIERY SYSTEMS
VANCOUVER, British Columbia--(BUSINESS WIRE)--Sept. 2, 2005--MIV
Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation
biocompatible stent coatings and drug delivery technologies
for the treatment of cardiovascular disease and therapeutic
applications on implantable medical devices, announced today
a milestone scientific achievement related to the development
of a new drug delivery system with "smart" drug-eluting coating
technologies. Full
Report - HTML |
| |
|
| |
MIVT:
MIVT THERAPEUTICS FURTHER EXPANDS IP PORTFOLIO WITH MILESTONE
ADDITON OF TWO NEW U.S. PROVISIONAL PATENT APPLICATIONS
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug.
30, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News), a developer
of next-generation biocompatible passive and drug-eluting stent
coatings and drug delivery technologies for the treatment of
cardiovascular disease, announced today a major milestone in
further expanding its intellectual property rights with the
filing of two new U.S. patent applications by the University
of British Columbia, a technology development partner of MIVT.
Full
Report - HTML |
| |
|
| |
MIVT:
MIVT RECEIVES PRESTIGIOUS FROST & SULLIVAN 2005 AWARD FOR
TECHNOLOGY INNOVATION IN FIELD OF MEDICAL COATINGS
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug.
24, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News), a developer
of next-generation biocompatible passive and drug-eluting stent
coatings and drug delivery technologies for the treatment of
cardiovascular disease, has been recognized by Frost & Sullivan
with the 2005 Technology Innovation Award, in recognition of
the Company's achievements and pioneering work to develop proprietary
biocompatible coatings technology to make better, safer vascular
stents, medical devices and drug delivery systems. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS CLOSES $4.14 MILLION EQUITY FINANCING
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug.
22, 2005--MIV Therapeutics, Inc. (OTCBB: MIVT - News), a developer
of next-generation biocompatible stent coatings and drug delivery
technologies for cardiovascular stents and for broad range of
implantable medical devices, has recently closed a Reg S and
Rule 506 non-brokered private placement financing totaling $4.14
million. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS BRAKTHROUGH TECHNOLOGY PRAISED IN INDEPENDENT
RESEARCH SERVICE BY FROST & SULLIVAN
MIV VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug.
17, 2005--MIV Therapeutics, Inc. (OTCBB: MIVT - News), a developer
of next-generation biocompatible and drug-delivery coatings
for cardiovascular stents, has been extolled as one of the leading
companies in the field of advanced medical coatings in a newly
released research service from Frost & Sullivan, a highly
respected global independent research and growth consulting
firm. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS SUCCESSFULLY COMPLETES ANIMAL FEASIBILITY STUDIES
OF STROKE-PREVENTION DEVICES
MIV Therapeutics, Inc. (OTCBB:MIVT - News), a
developer of next-generation biocompatible stent coatings and
drug delivery technologies, has successfully completed Phase
I animal feasibility studies in sheep of two models of a novel
implantable arterial filtration technology device designed to
prevent strokes by diverting embolic particles flowing through
the bloodstream. These two models of MIVT's unique Aortic Embolic
Protection Device (AEPD) are being designed to prevent both
major types of embolic strokes -- those triggered by heart surgery
and catheterization, and those that occur naturally, not in
connection with such procedures. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS SUCCESSFULLY COMPLETES ANIMAL FEASIBILITY STUDIES
OF STROKE-PREVENTION DEVICES
MIV Therapeutics, Inc. (OTCBB:MIVT - News), a
developer of next-generation biocompatible stent coatings and
drug delivery technologies, has successfully completed Phase
I animal feasibility studies in sheep of two models of a novel
implantable arterial filtration technology device designed to
prevent strokes by diverting embolic particles flowing through
the bloodstream. These two models of MIVT's unique Aortic Embolic
Protection Device (AEPD) are being designed to prevent both
major types of embolic strokes -- those triggered by heart surgery
and catheterization, and those that occur naturally, not in
connection with such procedures. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS GAINS 15% ON 4X AVERAGE VOLUME AND STOCK HITS
5-WEEK HIGH
July 11, 2005 (FinancialWire) MIV Therapeutics
gained 15.38% Friday on volume trading at 1,311,234, over 4.6
times the average volume of 285,017 to close at $0.75. MIV Therapeutics
stock has also reached a 5-week high and gained more than 40%
since the company's last update, which came on June 28. Full
Report - HTML |
| |
|
|
MIVT:
MIV THERAPEUTICS HITS FINACIAL TARGETS AND GOALS FOR FIRST SIX
MONTHS OF 2005
July 8, 2005 (FinancialWire) MIV Therapeutics,
Inc. (OTCBB: MIVT) has hit scientific and business achievements
in a corporate update. The company' noted their achievements
which include execution of a Letter of Intent to acquire the
world's third largest manufacturer of drug-eluting stents Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS GAINED 17% ON 4X AVERAGE VOLUME
July 6, 2005 (FinancialWire) MIV Therapeutics
Inc. (OTCBB: MIVT) gained 17.31% Tuesday on volume trading of
1,185,184, which is 4.4 times the average volume of 266,988
to close at $0.61.
Full Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS SPECULATIVE GAINS 11.77% INTRADAY ON 2X AVERAGE
VOLUME AFTER RESEARCH NOTE
June 30, 2005 (FinancialWire) (Investrend Research
Syndicate) MIV Therapeutics (OTCBB: MIVT) gained 11.77% intraday
to $0.57 before closing at $0.51 on volume of 435,318, almost
twice the average volume of 279,442 after Ernest C. Schlotter,
a senior analyst with InvesTrend affiliate SISM Research reiterated
his Speculative Buy/4 rating for MIV Therapeutics (OTCBB: MIVT)
with a 12-month price target of $1.50 .
Full Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS SPECULATIVE BUY/4 RATING $1.50 REITERATED BY
INVESTREND RESEARCH AFFILATE SISM RESEARCH
June 29, 2005 (FinancialWire) (Investrend Research Syndicate)
Ernest C. Schlotter, a senior analyst with InvesTrend affiliate
SISM Research, and a four-star analyst according to San Francisco-based
StarMine, has reiterated his Speculative Buy/4 rating for MIV
Therapeutics (OTCBB: MIVT) with a 12-month price target of $1.50
after the company announced that its HAp-coated cardiovascular
stents demonstrate excellent safety and feasibility at 3-month
follow-up after porcine implantation.
Full Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS ANNOUNCES AVAILABILITY OF RESEARCH REPORT PROJECTING
300% SHARE VALUE INCREASE IN 12 MONTHS
VANCOUVER, British Columbia--(BUSINESS WIRE)--June 28, 2005--MIV
Therapeutics, Inc. (OTCBB:MIVT), a developer of next-generation
biocompatible stent coatings and drug delivery technologies,
has announced the availability of an extensive research and
investment report by SISM Research & Investment Services
that projects a 300% increase in share appreciation, and reaffirms
a Speculative Buy/4 recommendation of the Company's stock with
a 12-month target price of $1.50.
Full Report - HTML
Summary in PDF |
| |
|
| |
MIVT:
MIV THERAPEUTICS REPORTS ON SUCCESSFUL PROGRESS OF ANIMAL STUDIES
OF HYDROXYAPATITE IN PREPARATION FOR CLINICAL TRIALS
VANCOUVER, British Columbia--(BUSINESS WIRE)--June 23, 2005--MIV
Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation
biocompatible stent coatings and drug delivery technologies,
has announced that its proprietary Hydroxyapatite (HAp) stent
coating has demonstrated excellent performance and biocompatibility
in key areas assessed at the three-month follow-up stage of
an ongoing study in which HAp-coated stents were implanted in
pig cardiovascular arteries. The results of the study, conducted
at The Methodist Hospital Research Institute in cooperation
with Texas Heart Institute, pave the way for upcoming human
clinical trials of HAp coatings for stents.
Full Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS EXERCISES OPTION TO LICENSE ADDITIONAL PROPRIETARY
TECHNOLIGES FOR BIOCOMPATIBLE DRUG-ELUTING COATINGS
VANCOUVER, British Columbia--(BUSINESS WIRE)--June 8, 2005--MIV
Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation
biocompatible stent coatings and drug delivery technologies,
announced it has exercised the option provided in its Collaborative
Research Agreement with the University of British Columbia (UBC)
to license two additional technologies for advanced biocompatible
and drug-eluting coatings for cardiovascular stents and other
medical devices. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS FEATURED IN RESPECTED EUROPE-BASED MEDICAL
INDUSTY PUBLICATION CARDOPVASCULAR NEWS
VANCOUVER, British Columbia--(BUSINESS WIRE)--June 6, 2005--MIV
Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation
biocompatible stent coatings and drug delivery technologies,
announced that the Company has been featured in a recent edition
of respected European medical industry publication, Cardiovascular
News. The article discussed the Company's recently announced
agreement to acquire Sahajanand Medical Technologies (SMT),
a manufacturer of advanced drug-eluting coronary stents based
in Surat, India. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS NAMES DHIRAJLAL KOTADIA, CEO OF SAHAJANAND,
AS CO-CHAIRMAN AND MANAGING DIRECTOR OF INTERNATIONAL OPERATIONS
British Columbia--(BUSINESS WIRE)--May 24, 2005-- MIV Therapeutics
Inc., (OTCBB: MIVT - News) a developer of next-generation biocompatible
coatings and drug delivery technologies, announced today that
it has appointed successful business and biomedical technology
innovator Dhirajlal Kotadia, founder and CEO of India-based
advanced stent manufacturer Sahajanand Medical Technologies,
to the position of Co-Chairman and Managing Director of International
Operations for MIVT. Full
Report - HTML |
| |
|
| |
MIVT:
SMALLCAP SENTINEL: STENT COMPANY LOOKS TO ENHANCE “FLOW“
OF BIOCOMPATIBLE DEVICE TECHNOLOGY
IRVINE, Calif., May 20, 2005 (PRIMEZONE) -- An informational
report on a biotech company developing technology to increase
the safety and effectiveness of drug-coated cardiovascular stents
has been made available free of charge to readers of SmallCap
Sentinel. This news comes on the heels of a new announcement
by MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) detailing
the expansion of the company's intellectual property portfolio
of next-generation biocompatible medical device coatings. Full
Report - HTML |
| |
MIVT:
MIV THERAPEUTICS EXPANDS INTELLECTUAL PROPERTY PORTFOLIO WITH
NEW TECHNOLIGES FOR NEXT-GENERATION BIOCOMPATIBLE MEDICAL DEVICE
COATINGS
Proprietary Technologies, Licensed from Univ. of British Columbia,
Include New Coatings for Advanced Drug-Eluting Applications.
Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS COMMENCES ANIMAL TRIALS OF STROKE-PREVENTING
PROPRIETARY DEVICE DEVELOPED BY RECENTLY-ACQUIRED SAGAX
IRVINE, MIV Therapeutics Commences Animal Trials of Stroke-Preventing
Proprietary Device Developed by Recently-Acquired SagaX. Revolutionary
Filter Designed to Significantly Reduce Risk of Cardioembolic
Stroke Caused by Cardiac Procedures. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS MEDICAL OFFICER DR. DOV SHIMON
INTERVIEWED BY BIOMEDDISCOVERIES.COM ABOUT NEW CLINICAL EVIDENCE
OF STENT RISKS
MIV Therapeutics Medical Officer Dr. Dov Shimon Interviewed
by BiomedDiscoveries.com about New Clinical Evidence of Stent
Risks Study in Journal of the American Medical Association Finds
Higher Rate of Complications and Death with Industry-Leading
Drug-Coated Stents. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS INC. RATED “OUTPERFORM“, TARGET
$1.53 BY INVESTREND AFFILIATE BEACON EQUITY RESEARCH
NEW YORK--(BUSINESS WIRE)--April 26, 2005--(Investrend Research
Syndicate) MIV Technologies, Inc. (OTCBB: MIVT - News) has been
rated "Outperform," with a price target of $1.53 by Investrend
Research affiliate Beacon Equity Research. The report is authored
by Senior Research Analyst, Shailesh Dhuri. Full
Report - HTML |
| |
|
| |
MIVT:
FOURTEEN UNDER-RECOGNIZED COMPANIES PRESENT
NEW OPPORTUNITIES THIS SATURDAY AT THE SCIA NATIONAL SMALL CAP
SOUTHERN CALIFORNIA INVESTMENT CONFRENCE IN ORGANGE COUNTY.
MONARCH BEACH,
CA--(MARKET WIRE)--Mar 30, 2005 -- Southern California Investment
Association, Inc. -- SCIA -- important small cap conference
from 7:15 a.m. - 1 p.m. to this Saturday, April 2nd, at the
Orange County Airport Hilton (800-Hiltons), 18800 MacArthur
Boulevard, Irvine, CA 92612, conveniently located across from
the John Wayne Airport (SNA). Registration required. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS REICEIVES GOVERNMENT GRANT
TO EXPEDITE DEVELOPMENT OF PROPRIETARY HAP STENT COATING FOR
DRUG DELIVERY TECHNOLOGIES
VANCOUVER,
B.C.--(BUSINESS WIRE)--March 22, 2005--MIV Therapeutics Inc.
(MIVT: OTCBB) announced today that its wholly-owned subsidiary,
MIVI Technologies Inc., that is involved in the research and
development of multilayer coating technologies with drug eluting
capability for cardiovascular stents and other implantable devices,
has received a Government grant for the research program titled
"Development of Novel Drug Eluting Composite Coatings for Cardiovascular
Stents". The National Research Council approved MIVI's application
following an in depth familiarization with the advanced concept
of novel technologies proposed by MIVI, and a review of the
Company's organizational and fiscal capability to carry on with
the proposed USD 1 million+ R&D program. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS COMPLETES ACQUISTIONN OF
SAGAX, DEVELOPER OF ADVANCED STROKE PREVENTION TECHNOLOGY
VANCOUVER,
B.C.--(BUSINESS WIRE)--March 18, 2005-- MIV Therapeutics, Inc.
(OTCBB: MIVT - News) a developer of next-generation biocompatible
coatings and drug delivery technologies, announced today that
it has executed an agreement to acquire SagaX Medical Technologies,
Inc., a company developing a range of proprietary solutions
that decrease likelihood of strokes and other frequently-occurring,
serious complications that can result from cardiac procedures,
as well as naturally occurring Cardioembolic Strokes. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS CEO DISCUSSES COMPANY’S
ADVANCED STENT TECHNOLOGY IN ONLINE INTERVIEW WITH SAMLLCAPINSIGHTS.COM
LOS ANGELES--(BUSINESS
WIRE)--March 17, 2005--SmallcapInsights.com, http://www.SmallcapInsights.com,
the online source for exclusive commentary, research, interviews
and other key investor information, has announced the availability
of an audio interview with Alan Lindsay, CEO of MIV Therapeutics,
a developer of next-generation biocompatible coatings and drug
delivery technologies. Full
Report - HTML |
| |
|
| |
MIVT:MIV
THERAPEUTICS GAINS 26.32% ON 10X AVERAGE VOLUME
March 16, 2005
(FinancialWire) MIV Therapeutics (OTCBB: MIVT) gained 26.32%
Tuesday on volume of 2,461,227, ten times its average volume
of 243,681, to close at $0.60. MIV Therapeutics is covered by
Investrend Research affiliate SISM Research's analyst, Ernest
C. Schlotter. On September 22, 2003, Schlotter initiated coverage
with a "Buy" rating and a $1.50 target, which was reiterated
June 18. 2004 SISM Research is distributed by the Investrend
Research Syndicate. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS GAINES 39.71% ON 15X AVERAGE VOLUME, WILL PARTICIPATE
IN WEBCAST
March 15, 2005
(FinancialWire) MIV Therapeutics (OTCBB: MIVT) gained 39.71%
Monday on volume of 3,147,693, some 15 times its average volume
of 200,818, to close at $0.475. At the same time, it was announced
that the company, along with Xenomics (OTCBB: XNOM) and Biophan
Technologies (OTCBB: BIPH), will present at a webcast March
23, beginning at noon. The webcast is sponsored by Trilogy Capital
Partners. The conference moderator is A.J. Cervantes, president
of Trilogy, and the keynote speaker will be Dr. John Faessel.
Registration for the event is at http://www.trilogy-capital.com
MIV Therapeutics is covered by Investrend Research affiliate
SISM Research's analyst, Ernest C. Schlotter. On September 22,
2003, Schlotter initiated coverage with a "Buy" rating and a
$1.50 target, which was reiterated June 18.. SISM Research is
distributed by the Investrend Research Syndicate.
. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS ANNOUNCES 2004 YEAR-END REVIEW:
MILESTONES ACHIEVED IN DEVELOPMENT OF REVOLUTINARY COATINGS
FOR MEDICAL DEVICES
VANCOUVER,
British Columbia--(BUSINESS WIRE)--March 15, 2005--MIV Therapeutics
Inc., a developer of next-generation drug-eluting coatings that
inhibit the rejection of implanted medical devices, has announced
the Company's successful achievement of all key milestones planned
in its 2004 research and development program. The Company is
progressing toward commercialization of a revolutionary new
surface coating technology that has the potential to vastly
improve the human body's acceptance of implanted medical devices,
as well as enhance the functionality of those devices. The announcement
was made by Alan Lindsay, President and CEO of MIVT. Technology
Increases Body's Acceptance of Implanted Devices, Provides Advanced
Therapeutic Functionality. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPETEUTICS AND SAHAJANAND MEDICAL
TECHNOLOGIES TO JOIN FORCES TO FORM WORLD CLASS DRUG-ELUTING
CORONARY STENT COMPANY
VANCOUVER,
B.C.--(BUSINESS WIRE)--March 11, 2005--MIV Therapeutics Inc.,
a developer of next-generation biocompatible coatings and drug
delivery technologies, announced today that it has executed
a letter of intent to acquire Sahajanand Medical Technologies,
one of the world's largest manufacturers of advanced coronary
stents. Alan Lindsay, Chairman, President and CEO of MIVT, made
the announcement. Transaction will Bring Company $20 Million
Approximate Annual Revenues and International Production and
Distribution.
Full Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS INC.’S HAP NANO STENT
COATING DEMONSTRATES EXCELLENT BIOCOMPATIBILTY AND SAFETY IN
CORONARY ARTERIES
VANCOUVER,
British Columbia--(BUSINESS WIRE)--March 8, 2005--MIV Therapeutics
Inc., a developer of next-generation drug-eluting coatings that
inhibit the rejection of implanted medical devices, announced
today the successful completion of pilot preclinical studies
of hydroxyapatite (HAp) coated stents in pig coronary arteries.
The histopathology studies that followed angiographic and intravascular
ultrasound evaluation confirmed excellent biocompatibility and
safety of its proprietary hydroxyapatite (HAp) coating for vascular
applications. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS GAINS 20% ON 10X AVERAGE
VOLUME AFTER SAGAX DEAL ANNOUNCED
February 23, 2005 (FinancialWire) February 23,
2005 (FinancialWire) MIV Therapeutics (OTCBB: MIVT) gained 20%
Tuesday on volume of 904,417, ten times its average volume of
83,863, to close at $0.30 after the company and SagaX Medical
Technologies Inc. (SagaX), announced they had entered into a
letter of intent regarding SagaX' next generation embolic-protection
technology for stroke patients. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS GAINS 20% ON 10X AVERAGE
VOLUME AFTER SAGAX DEAL ANNOUNCED
February 23, 2005 (FinancialWire) February 23,
2005 (FinancialWire) MIV Therapeutics (OTCBB: MIVT) gained 20%
Tuesday on volume of 904,417, ten times its average volume of
83,863, to close at $0.30 after the company and SagaX Medical
Technologies Inc. (SagaX), announced they had entered into a
letter of intent regarding SagaX' next generation embolic-protection
technology for stroke patients. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAEUTICS INC. AND SAGAX MEDICAL TECHNOLOGIES
INC. SIGN LETTER OF INTENT FOR NEXT GENERATIN EMBOLIC-PROTECTION
TECHNOLOGY
VANCOUVER, Feb. 22 /PRNewswire-FirstCall/ - MIV
Therapeutics Inc., (OTCBB: MIVT - News) and SagaX Medical Technologies
Inc. (SagaX), announced today that they have entered into a
letter of intent regarding SagaX' next generation embolic-protection
technology for stroke patients. The parties hope to negotiate
and execute definitive agreements regarding the transaction
within the next few weeks. Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS GAINS 45.95% ON 6X AVERAGE
VOLUME AFTER INDEPENDENT RESEARCH
February 17, 2005 (FinancialWire) MIV Therapeutics
Inc., (OTCBB: MIVT) gained 45.95% on volume of 524,162, six
times its average volume of 89,954, to close at $0.27, in the
first session after the announcement that Investrend Research
affiliate SISM Research reinforced it's Speculative Buy/4 Rating
for the company. Full
Report - HTML |
| |
|
| |
MIVT:
SISM RESEARCH ANALYST REINFORCES SPECULATIVE
BUY/4 RATING FOR MIV THERAPEUTICS INC.
VANCOUVER, Feb. 15 /PRNewswire-FirstCall/ - In
a Research Report dated February 10, 2005, SISM Research reinforced
its SPECULATIVE BUY/4 Rating for MIV Therapeutics Inc., (OTCBB:
MIVT) a developer of next-generation drug-eluting coatings that
inhibit the rejection of implanted medical devices. SISM Research,
leading European market analyst, noted that despite being significantly
undervalued and still lacking awareness within the investor
community, MIV Therapeutics enjoys strong fundamentals and has
never been in a better position to move ahead with the development
of its revolutionary, fully biocompatible hydroxyapatite (HAp)
coating technology. Full
Report - HTML Summary
in PDF |
| |
|
| |
MIVT:
MIV THERAPEUTICS INC.
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD
ENDED NOVEMBER 30, 2004 Full
Report - HTML |
| |
|
| |
MIVT:
MIV THERAPEUTICS INC.
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD
ENDED AUGUST 31, 2004 Full
Report - HTML |
| |
|
| 10.07.04 |
MIVT: MIV THERAPEUTICS
INC. – HAP COATING SUCCESSFULLY COMPLETES PORCINE CORONARY
IMPLANTATION TRIALS
VANCOUVER, Oct. 7 /PRNewswire-FirstCall/ - MIV Therapeutics
Inc. (MIVT:OTCBB), announced today the successful completion
of the pilot in vivo Pilot Coronary Arteries Implantation Studies
on its proprietary, biocompatible Hydroxyapatite (HAp) nano-film
coating, designated for passive application on cardiovascular
stents and other implantable medical devices. Report
in HTM |
| |
|
| 09.13.04 |
MIVT: MIV THERAPEUTICS
HAP COATING SUCCESSFULLY COMPLETES SAFETY TRIAL
VANCOUVER, Sept. 13 /PRNewswire-FirstCall/ - MIV Therapeutics
Inc. (MIVT:OTCBB), announced today the successful completion
of in vivo safety studies on its proprietary, biocompatible
Hydroxyapatite (HAp) nano-film coating, designated for passive
application on cardiovascular stents and other implantable medical
devices. The results of this study have shown that the stent
coating is safe and did not cause any adverse arterial response.
Report
in HTM |
| |
|
| 09.08.04 |
MIVT: MIV THERAPEUTICS
VICE PRESIDENT NOMINATED FOR 2004 WORLD TECHNOLOGY AWARD
Sep 8, 2004 (financialwire.net via COMTEX) -- (FinancialWire)
MIV Therapeutics Inc. (OTCBB: MIVT) said that Dr. Tom Troczynski,
Ph.D., Vice President of Coatings and Professor of Ceramics
at The University of British Columbia, has been selected as
a nominee for the 2004 World Technology Award in Energy at this
year's World Technology Awards, being held in association with
NASDAQ (OTCBB: NDAQ), Microsoft (NASDAQ: MSFT), and Time Warner's
(NYSE: TWX) Time Magazine, Science magazine, and CNN. Report
in HTM |
| |
|
| 08.30.04 |
MIVT: MIV THERAPEUTICS
INC FILES SEC FORM 10KSB, ANNUAL REPORT
Annual report under Section 13 or 15 (d) of the Securities Exchange
Act of 1934 for the fiscal year ended: May 31, 2004 Report
in HTM |
| |
|
| 06.28.04 |
MIVT: MIV THERAPEUTICS
INC. COMPLETES SIGNIFICANT BIOCOMPATIBILITY MILESTONES FOR HAP
COATING TECHNOLOGY
VANCOUVER, Jun 28, 2004 /PRNewswire-FirstCall via COMTEX/ --
MIV Therapeutics Inc. (OTCBB:MIVT), announced today that it
has successfully completed the full range of biocompatibility
studies on its proprietary, biocompatible hydroxyapatite (HAp)
ultra-thin coating technology. The coating is designated for
passive and drug-eluting application on cardiovascular stents
and other implantable medical devices. Toxikon Corporation,
Bedford, MA, was commissioned by MIVT to perform the complete
range of 12 biocompatibility tests which are summarized:Report
in HTM |
| |
|
| 06.23.04 |
MIVT: MIV THERAPEUTICS
PRESENTS STENT COATING AT 7TH WORLD BIOMATERIALS CONGRESS
NEW YORK Jun 23, 2004 (financialwire.net via COMTEX) - (FinancialWire)
MIV Therapeutics Inc. (OTCBB: MIVT) said its proprietary, biocompatible
Hydroxyapatite (HAp) ultra- thin coating technology for passive
and drug-eluting applications on cardiovascular stents and other
implantable medical devices was presented by MIVT at the 7th
World Biomaterials Congress in Sydney, Australia, May 17-21,
2004. Report
in HTM |
| |
|
| 06.21.04 |
MIVT: MIV THERAPEUTICS
GAINS 7.32% FRIDAY AFTER INDEPENDENT RESEARCH NOTE
NEW YORK Jun 21, 2004 (financialwire.net via COMTEX) -- (FinancialWire)
MIV Therapeutics, Inc. (OTCBB: MIVT; Berlin: MIV1) gained 7.32%
to close at $0.44, after rising to $0.47 intraday, on volume
of 31,263 Friday, after Ernest C. Schlotter, analyst at Investrend
affiliate SISM Research, reiterated his Buy Recommendation for
MIV Therapeutics, Inc. (OTCBB: MIVT; Berlin: MIV1), with a 12-month
price target of $1.50. Report
in HTM |
| |
|
| 06.18.04 |
MIVT: MIV THERAPEUTICS
REITERATED AT BUY WITH $1.50 TARGET, BY INVESTREND AFFILIATES
SISM RESEARCH
NEW YORK Jun 18, 2004 (financialwire.net via COMTEX) -- (FinancialWire)
(Investrend Research Syndicate) Ernest C. Schlotter, analyst
at Investrend affiliate SISM Research, has reiterated his Buy
Recommendation for MIV Therapeutics, Inc. (OTCBB: MIVT; Berlin:
MIV1), with a 12-month price target of $1.50. Summary
in PDF |
| |
|
| 06.17.04 |
MIVT: MIV THERAPEUTICS
BIOCOMPATIBLE STENT COATING SUCCESSFULLY COMPLETES PYROGEN TRIAL
VANCOUVER, June 17 /PRNewswire-FirstCall/ - MIV Therapeutics
Inc. (MIVT:OTCBB), announced today that its proprietary Hydroxyapatite
(HAp) ultra-thin "passive" stent coating has successfully passed
the Rabbit Pyrogen Test (Material Mediated) - ISO confirming
that the coating is non-pyrogenic and does not induce fever.
Report
in HTM |
| |
|
| 06.10.04 |
MIVT: MIV THERAPEUTICS
INC. RETAINS STRATEGIC GROWTH AS INVESTOR RELATIONS ADVISOR
JUNE 3, VANCOUVER, June 10 /PRNewswire-FirstCall/ - MIV Therapeutics
Inc. (MIVT:OTCBB) a company developing the next generation of
coatings for drug delivery on stents and medical devices is
pleased to announce it has retained the services of Strategic
Growth International Inc. (SGI), to provide global exposure
to the investment community. Report
in HTM |
| |
|
| 06.03.04 |
MIVT: MIV THERAPEUTICS
TRADES UP 18.60% ON 2X AVERAGE VOLUME.
JUNE 3, 2004 (financialwire.net via COMTEX) -- (FinancialWire)
MIV Therapeutics traded up 18.60%, to close at $0.51, on volume
of 358,735 Wednesday, approximately two times its average volume
of 186,519. MIV Therapeutics is covered by Investrend Research
affiliate SISM Research's analyst, Ernest C. Schlotter. On September
22, 2003, Schlotter initiated coverage with a "Buy" rating and
a $1.50 target, which was reiterated October 19. SISM Research
is distributed by the Investrend Research Syndicate. |
| |
|
| 06.01.04 |
MIVT: US PATENT ISSUED
FOR DRUG ENCAPSULATION APPLICATION OF MIV THERAPEUTICS’
BIOCOMPATIBLE DRUG ELUTING COATING TECHNOLOGY. VANCOUVER,
June 1 /PRNewswire-FirstCall/ - MIV Therapeutics Inc. (MIVT:OTCBB)
is pleased to announce today that the United States Patent and
Trademark Office has awarded The University of British Columbia
(UBC) a patent relating to MIVT's licensed biocompatible hydroxypatite
(HAp) coating technology. MIVT has the exclusive worldwide license
from UBC to use and sublicense the HAp coating technologies
for the development, manufacture and sale of coated stents and
other implantable medical devices as drug delivery systems.
Report in HTM |
| |
|
| 04.26.04 |
MIVT: MIV THERAPEUTICS
WELCOMES DR. KEON, MEDICAL ADVISOR AND CHAIRMAN OF THE SCIENTIFIC
ADVISORY BOARD
VANCOUVER, Apr 26, 2004 /PRNewswire-FirstCall via COMTEX/
-- MIV Therapeutics Inc. (MIVT:OTCBB & MIV1:BE) is pleased
to announce that Dr. Wilbert Keon, O.C., M.D., F.R.C.S.(C) has
accepted the Company's invitation to act as Medical Advisor
and as Chairman of the Scientific Advisory Board.
Report in PDF |
| |
|
| 04.21.04 |
MIVT: MIV THERAPEUTICS
ANNOUNCES AN ADDITIONAL $700,00 PRIVATE PLACEMENT COMPANY RAISES
MORE THAN $3 MILLION IN MARCH AND APRIL, 2004
VANCOUVER, BC, Apr 21, 2004 /PRNewswire-FirstCall via
COMTEX/ -- MIV Therapeutics Inc. (MIVT:OTCBB & MIV1.BE:
Berlin) announced today that it has raised additional funds
necessary for completion of the next stage of its research and
development program leading towards commercialization of its
proprietary biocompatible coating technology developed for cardiovascular
stents and other medical devices.
Report in PDF |
| |
|
| 03.30.04 |
MIVT: HEMOLYSIS TEST PRODUCES
SUCCESSFUL RESULTS FOR MIV THERAPEUTIC’S ULTRA-THIN HYDROXYAPATITE
COATING TECHNOLOGY
VANCOUVER, Mar 30, 2004 /PRNewswire-FirstCall via COMTEX/
-- MIV Therapeutics Inc. (MIVT:OTCBB & MIV1.BE: Berlin),
announced today that its proprietary, biocompatible Hydroxyapatite
(Hap) ultra-thin coating for passive and drug- eluting application
on cardiovascular stents and other implantable medical devices
has passed another significant biocompatibility test, the Hemolysis
- Rabbit Blood - Test (ISO).
Report in PDF |
| |
|
| 03.25.04 |
MIVT: VFINANCE ISSUES REPORT
ON DRUG-ELUTING STENT TECHNOLOGY
NEW YORK--(BUSINESS WIRE)--March 25, 2004--vFinance Investments,
Inc. (OTCBB:VFIN), a leading financial services firm providing
research, investment banking and brokerage services to corporate,
institutional and private clients, has released a sector report
analyzing the impact Drug-Eluting Stent (DES) technology will
have on the medical device industry. The report identifies those
firms that have the most to gain and lose for the adoption of
DES.
Report in HTM |
| |
|
| 03.24.04 |
MIVT: MIV THERAPEUTICS
ULTRA-THIN HYDROXYAPATITE COATING TECHNOLOGY FOR CARDIOVASCULAR
STENTS SUCCESSFULLY COMPLETES KEY SYSTEMIC INJECTION TEST
VANCOUVER, Mar 24, 2004 /PRNewswire-FirstCall via COMTEX/
-- MIV Therapeutics Inc. (MIVT:OTCBB & MIV1.BE: Berlin)
announced today that the Company's proprietary Hydroxyapatite
(Hap) ultra-thin coating technology has successfully passed
the Systemic Injection Test (ISO), an important milestone on
the path to commercialization. MIV Therapeutics is developing
a line of "next generation", biocompatible coatings for stents
and drug delivery systems for the treatment of cardiovascular
disease. The technology is an attractive alternative to the
bare-metal stent and could provide a significant benefit to
the population who cannot afford drug-eluting stents. The technology
also has applications for non-vascular disorders.
Report in PDF |
| |
|
| 03.24.04 |
MIVT: MIV THERAPEUTICS
ULTRA-THIN HYDROXYAPATITE COATING TECHNOLOGY FOR CARDIOVASCULAR
STENTS SUCCESSFULLY COMPLETES KEY SYSTEMIC INJECTION TEST
VANCOUVER, Mar 24, 2004 /PRNewswire-FirstCall via COMTEX/
-- MIV Therapeutics Inc. (MIVT:OTCBB & MIV1.BE: Berlin)
announced today that the Company's proprietary Hydroxyapatite
(Hap) ultra-thin coating technology has successfully passed
the Systemic Injection Test (ISO), an important milestone on
the path to commercialization. MIV Therapeutics is developing
a line of "next generation", biocompatible coatings for stents
and drug delivery systems for the treatment of cardiovascular
disease. The technology is an attractive alternative to the
bare-metal stent and could provide a significant benefit to
the population who cannot afford drug-eluting stents. The technology
also has applications for non-vascular disorders.
Report in PDF |
| |
|
| 03.22.04 |
MIVT: MIV THERAPEUTICS
ANNOUNCES $2.34 MILLION PRIVATE PLACEMENT
VANCOUVER, Mar 22, 2004 /PRNewswire-FirstCall via COMTEX/
-- MIV Therapeutics Inc. (MIVT:OTCBB & MIV1.BE: Berlin)
announced today that it has raised funds necessary for completion
of the next stage of its research and development program leading
towards commercialization of its proprietary biocompatible coating
technology developed for cardiovascular stents and other medical
devices.
Report in PDF |
| |
|
| 03.08.04 |
MIVT: MIV THERAPEUTICS
GAINS 16.67% ON 3X VOLUME AFTGER ‘PERFECT’ SCORE
FOR STENT COATING
Mar 9, 2004 (financialwire.net via COMTEX) -- (FinancialWire)
MIV Therapeutics (OTCBB: MIVT) gained 16.67% Monday, closing
at $0.80, on volume of 720,831, more than three times its average
volume, after the company said its proprietary ultra-thin coating
achieved another milestone by successfully passing an independent
assessment of cytotoxicity (biological reactivity) of Hydroxyapatite
(HAp), a coating material which is expected to become the coating
of choice for passive and drug eluting applications on cardiovascular
stents and other medical devices.
Report in PDF |
| |
|
| 03.08.04 |
MIVT: MIV THERAPEUTICS
ULTRA-THIN HYDROXYAPATITE COATING SCORES PERFECT RESULT DURING
BIOLOGICAL REACTIVITY (CYTOTOXICITY) TEST
TORONTO, March 8 /PRNewswire-FirstCall/ - MIV Therapeutics
Inc. (MIVT:OTCBB & MIV1.BE: Berlin) is pleased to announce
its proprietary ultra-thin coating achieved another milestone
by successfully passing an independent assessment of cytotoxicity
(biological reactivity) of Hydroxyapatite (HAp), a coating material
which is expected to become the coating of choice for passive
and drug eluting applications on cardiovascular stents and other
medical devices.
Report in HTML |
| |
|
| 03.02.04 |
MIVT: MIV THERAPEUTICS
GAINS 25.93% ON 9X AVERAGE VOLUME
Mar 2, 2004 (financialwire.net via COMTEX) -- (FinancialWire)
MIV Therapeutics (OTCBB: MIVT) gained 25.93% Monday on volume
of 1,569,281, about nine times its average volume of 164,841,
closing at $0.68. MIV Therapeutics is covered by Investrend
Research affiliate SISM Research's analyst, Ernest C. Schlotter.
On September 22, 2003, Schlotter initiated coverage with a "Buy"
rating and a $1.50 target, which was reiterated October 19.
SISM Research is distributed by the Investrend Research Syndicate.
Report in PDF |
| |
|
| 03.01.04 |
MIVT: MIV THERAPEUTICS
IS FEATURED BY SPECIAL SITUATIONS ANALYST Investor Alert:
Biotech Firm Developing Major Cardiac Device Breakthrough. Introducing
unique biocompatible coatings for stents in the treatment of
cardiovascular disease – new applications are designed
to revolutionize multibillion market for cardiac medical devices.
Company expecting results of crucial trials – this year.
Report in PDF |
| |
|
| 02.26.04 |
MIVT: MIV THERAPEUTIC’S
R&D TEAM MAKES IMPACT ON SCIENCE OF BIOMATERIALS
VANCOUVER, Feb. 26 /PRNewswire-FirstCall/ - Chairman
of The Board and Chief Executive Officer of MIV Therapeutics
Inc. (MIVT:OTCBB & MIV.BE: Berlin) announced today that
the MIVT R&D team, in collaboration with the UBC team of
scientists, will present three papers at the 7th World Biomaterials
Congress (http://www.tourhosts.com.au/biomaterials/invit.html)
in Sydney, Australia, May 17-21, 2004. One of the papers relates
directly to the revolutionary MIVT technology for HAp coated
stents, and is titled "Nanoporous Calcium Phosphate Thin Coatings
for Stents" (click here for full text of the extended abstract
of the paper). The second paper is titled "Mesoporous Bioglass
Films by Sol- Gel" (abstract), and the third paper relates to
HAp-based composite materials"
Report in HTM |
| |
|
| 02.11.04 |
MIVT: FIRST PHASE OF MIV
THERAPEUTICS CANADIAN R&D PROGRAM IS SUCCESS
Feb 11, 2004 (financialwire.net via COMTEX) -- (FinancialWire)
MIV Therapeutics (OTCBB: MIVT; BSE: MIV; Frankfurt: MIV1) said
it has successfully completed the first phase of its Hydroxyapatite
(HA) Drug-Eluting Stent Coating R&D Program sponsored in
part by the Canadian Government. The University of British Columbia
has submitted its final report to the Natural Sciences and Engineering
Research Council of Canada (NSERC) which provided a grant in
support of the research program entitled "Functionally Gradient
Calcium Phosphate Coatings for Stents."
Report in PDF |
| |
|
| 02.10.04 |
MIVT: MIV THERAPEUTICS
SUCCESSFULLY COMPLETES GOVERNMENT -SPONSORED DRUG-ELUTING STENT
COATING R&D PROGRAM
VANCOUVER, British Columbia, Feb 10, 2004 (Canada NewsWire
via COMTEX) -- MIV Therapeutics Inc. (OTC Bulletin Board: MIVT;
BSE: MIV; Frankfurt: MIV1) is pleased to announce that it has
successfully completed the first phase of its Hydroxyapatite
(HA) Drug-Eluting Stent Coating R&D Program sponsored in
part by the Canadian Government. The University of British Columbia
has submitted its final report to the Natural Sciences and Engineering
Research Council of Canada (NSERC) which provided a grant in
support of the research program entitled "Functionally Gradient
Calcium Phosphate Coatings for Stents." The research activities
were conducted by the University of British Columbia, UBCeram
-- Metals and Materials Engineering, in close cooperation with
MIVT's R&D team, under a Collaborative Research and Development
Agreement.
Report in PDF |
| |
|
| 02.03.04 |
MIVT: MIV THERAPEUTICS
CLOSES UP 11.11% ON 6X AVERAGE VOLUME
Feb 3, 2004 (financialwire.net via COMTEX) -- (FinancialWire)
MIV Therapeutics (OTCBB: MIVT) traded up 11.11% Monday to close
at $0.60, on volume of 796,677, approximately six times its
average volume of 127,000. MIV Therapeutics is covered by Investrend
Research affiliate SISM Research's analyst, Ernest C. Schlotter.
On September 22, 2003, Schlotter initiated coverage with a "Buy"
rating and a $1.50 target, which was reiterated October 19.
SISM Research is distributed by the Investrend Research Syndicate.
Report in PDF |
| |
|
| 02.02.04 |
MIVT: MIV THERAPEUTICS
CLOSES UP 22.73% ON 6X AVERAGE VOLUME
Feb 2, 2004 (financialwire.net via COMTEX) -- (FinancialWire)
MIV Therapeutics (OTCBB: MIVT) closed up 22.73% to $0.54 on
volume of 709,579, approximately six times its average volume
of 119,646. MIV Therapeutics is covered by Investrend Research
affiliate SISM Research's analyst, Ernest C. Schlotter. On September
22, 2003, Schlotter initiated coverage with a "Buy" rating and
a $1.50 target, which was reiterated October 19. SISM Research
is distributed by the Investrend Research Syndicate.
Report in PDF |
| |
|
| 01.20.04 |
MIVT:SUCCESSFUL FATIQUE
LIFE TEST CONFIRMS DURABILTY OF MIV THERAPEUTICS HYDROXYAPATITE
STENT COATING
VANCOUVER, Jan 20, 2004 /PRNewswire-FirstCall via COMTEX/
-- MIV Therapeutics Inc. (MIVT:OTCBB; MIV:BSE; MIV1:Frankfurt)
is pleased to announce that it has successfully completed an
essential fatigue life test of its proprietary hydroxyapatite
(HAp) stent coating. The test titled "In-Vitro 40 Million Cycle
Accelerated Fatigue Test for Stents with MIV Therapeutics' HAp
Coating" was conducted to evaluate the mechanical integrity
and bonding properties of MIVT's ultra-thin biocompatible coating.
Report
in PDF |
| |
|
| 01.20.04 |
MIVT:SUCCESSFUL TATIQUE
LIFE TEST CONFIRMS DURABILTY OF MIV THERAPEUTICS HYDROXYAPATITE
STENT COATING
VANCOUVER, Jan 20, 2004 /PRNewswire-FirstCall via COMTEX/
-- MIV Therapeutics Inc. (MIVT:OTCBB; MIV:BSE; MIV1:Frankfurt)
is pleased to announce that it has successfully completed an
essential fatigue life test of its proprietary hydroxyapatite
(HAp) stent coating. The test titled "In-Vitro 40 Million Cycle
Accelerated Fatigue Test for Stents with MIV Therapeutics' HAp
Coating" was conducted to evaluate the mechanical integrity
and bonding properties of MIVT's ultra-thin biocompatible coating.
Report
in PDF |
| |
|
| 12.18.03 |
MIVT: MIV THERAPEUTICS
SHARES EXPLODE ON MILESTONES REPORT
Dec 18, 2003 (financialwire.net via COMTEX) -- (FinancialWire)
The shares of MIV Therapeutics (OTCBB: MIVT) leapt 35.48% to
close at $0.42, on volume of 217,000, three times its average,
Wednesday after announcing it is meeting the critical path objectives
of its proprietary hydroxyapatite (HAp) stent coating Research
and Development (R&D) program. Report
in PDF |
| |
|
| 12.17.03 |
MIVT: MIV THERAPEUTICS’
HYDROXYAPATITE STENT COATING ACHIEVES SCIENTIFIC MILESTONES
ON SCHEDULE
VANCOUVER, Dec 17, 2003 /PRNewswire-FirstCall via Comtex/
-- MIV Therapeutics Inc. (MIVT:OTCBB; MIV:BSE; MIV1: Frankfurt)
is pleased to announce it is meeting the critical path objectives
of its proprietary hydroxyapatite (HAp) stent coating Research
and Development (R&D) program.Report
in PDF |
| |
|
| 11.04.03 |
MIVT: MIV THERAPEUTICS
WELCOMES DR. ARUN CHOCKALINGAM SPEICAL ADVISOR SCIENTIFIC &
INTERNATIONAL AFFAIRS
VANCOUVER, Nov 4, 2003 /PRNewswire-FirstCall via COMTEX/
-- MIV Therapeutics Inc. (MIVT:OTCBB & MIV1:FSE) is pleased
to announce that Dr. Arun Chockalingam, BE, MS, PhD, FACC, FACEP
has accepted our invitation to act as Special Advisor on Scientific
& International Affairs. Report
in PDF |
| |
|
| 10.30.03 |
MIVT: MIV THERAPEUTICS
INC. LISTED ON THE FRANFURT STOCK EXCHANGE
VANCOUVER, Oct 30, 2003 /PRNewswire-FirstCall via COMTEX/
-- MIV Therapeutics Inc. (MIVT.OB :OTC BB) is pleased to announce
the Company's listing application has met all admission requirements
and its Regulation S stock has been accepted for listing on
the Frankfurt Stock Exchange (Frankfurt WKN: 911285, MIV1.FSE).
MIVT will continue to trade on the NASDAQ OTC Bulletin Board.
Report
in PDF |
| |
|
| 10.17.03 |
MIVT: MIV THERAPEUTICS
TRADES NEARLY 2X VOLUME AFTER REPORT
Oct 17, 2003 (financialwire.net via COMTEX) -- (FinancialWire)
MIV Therapeutics, Inc. (OTCBB: MIVT; BE: MIV) traded 109,500
shares, almost twice its average volume of 62,992 following
the reiteration of a "Buy" rating and 6-month price target of
$1.50 by Investrend affiliate SISM Research following the company's
issuance of its Q1FY2004 financial results. Report
in PDF |
| |
|
| 10.16.03 |
MIVT: BUY RATING, $1.50
TARGET REITERATED FOR MIV THERAPEUTICS
We have reiterated our Buy rating and 6-month price
target of $1.50 for MIV Therapeutics, Inc. following the Company's
issuance of its Q1FY2004 financial results. MIV Therapeutics
reported financial results for Q1FY2004 with a net loss for
the quarter of $689,565 or ($0.03) per share compared with a
net loss of $722,630 or ($0.04) per share for the same period
one year ago. We estimated, for Q1FY04, a net loss of $530,000
or ($0.02) per share. The Company incurred an operating loss
for the quarter, primarily because of research and development
concerning its proprietary coating technology, animal trials
and general administration costs. During the three months ended
August 31, 2003, MIV Therapeutics focused on continuing research
and development of new therapeutic technologies and on its biocompatible
coating for stent and drug delivery systems. During this period
of time, the Company initiated the transfer of technology from
the University of British Columbia to its own premises with
a focus on the introduction of proper process controls and volume
production. Report
in PDF |
| |
|
| 10.12.03 |
MIVT: MIV THERAPEUTICS
FEATURED ON EURONEWS TV MONDAY
Oct 12, 2003 (financialwire.net via COMTEX) -- (FinancialWire)
MIV Therapeutics Inc. (OTCBB: MIVT) will be featured on EuroNews
Television, reaching over 150 million households, Monday, October
13, between 11 p.m. and 11:20 p.m.,Central European Time. Report
in PDF |
| |
|
| 10.06.03 |
MIVT: ANALYST REPORT ON
MIV THERAPEUTICS FETURED IN ‘THE STENTING NEWSLETTER’
Oct 6, 2003 (financialwire.net via COMTEX) -- (FinancialWire)
“The Stenting Newsletter," a global compilation of cardiovacular-related
news issued by leading public companies such as Edwards Lifesciences
Corp. (NYSE: EW), Medtronic (NYSE: MDT) and Thoratec Corp. (NASDAQ:
THOR), as well as worldwide conferences and seminars, features
the analyst report on MIV Therapeutics, Inc. (OTCBB: MIVT) in
its October 6 edition. Report
in PDF |
| |
|
| 09.25.03 |
MIVT: MIV THERAPEUTICS
GETS MILESTONE REPORT
Sep 25, 2003 (financialwire.net via COMTEX) -- (FinancialWire)
MIV Therapeutics Inc. (OTCBB: MIVT:OTCBB; BE: MIV) has received
a mid-point milestone interim progress report from the University
of British Columbia (UBC) on the development of its proprietary
HAp (hydroxyapatite) multi-layer coating with drug-eluting capabilities.ave
reiterated our Buy rating and 6-month price target of $1.50
for MIV Therapeutics Report
in PDF |
| |
|
| 09.16.03 |
MIVT: MIV THERAPEUTICS
COVERGE INITIATED BY SISM RESEARCH ANALYST ERNEST C. SCHLOTTER
Sep 16, 2003 (financialwire.net via COMTEX) -- (FinancialWire)
(Investrend Research Syndicate) Coverage of MIV Therapeutics
Inc. (OTCBB: MIVT; BE: MIV) has been initiated by Ernest C.
Schlotter, a research analyst with SISM Research & Investment
Services, an Investrend Research affiliate. Report
in PDF |
| |
|
| 09.16.03 |
MIVT: INITIAL COVERAGE
WITH A BUY RATING
MIV Therapeutics Inc.’s corporate mission is to become
a world leader in the development of coatings for stents and
drug delivery systems for the treatment of cardiovascular disease
(with an emphasis on reducing restenosis) and for localized
drug delivery to other diseased organs of the body. MIVT is
in late stage development of its unique proprietary hydroxyapatite
coating technology, which is covered by patents filed by the
Company’s strategic partner, the University of British
Columbia. This HAp coating technology could revolutionize the
current $2.6 billion coronary stent market. MIVT’s HAp
coating is a unique nanofilm technology that is different from
the polymers currently being developed and offered by the industry
for stent drug delivery systems. The enormous potential of this
industry is shown in the stock valuation of Angiotech (NASDAQ:NM
ANPI), a company with a $1.78 billion market cap, something
that was achieved as an R&D company with a focus on developing
polymer-based coatings for stent drug delivery systems. MIVT’s
current low $15.6m market capitalization offers a significant
upside and heavily discounts the potential for success in both
animal and clinical trials. If these trials prove to be successful,
we believe MIVT’s stock will rise significantly. Summary
in PDF |